Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CS1-targeted CAR-T cells
- Development stage
- Phase 1
- Lead developer
- Zhejiang University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
CS1-targeted CAR-T cells is an investigational autologous chimeric antigen receptor (CAR) T-cell therapy being developed by Zhejiang University in collaboration with Yake Biotechnology for the treatment of relapsed or refractory multiple myeloma. The therapy consists of autologous T cells genetically modified to express a CAR that targets CS1 (also known as SLAMF7 or CD319), a cell surface glycoprotein highly and nearly universally expressed on malignant plasma cells. The CAR construct utilized in this program incorporates an anti-CS1 single-chain variable fragment (scFv) linked to CD28 costimulatory and CD3ζ signaling domains. This therapy is specifically being evaluated in clinical trials for patients who have relapsed after receiving BCMA-targeted CAR-T therapies, as well as those with CS1-positive/BCMA-negative disease, addressing a significant unmet need in advanced myeloma management.
- Other names
- CS1 Targeted CAR T-cellsCS-1 Targeted CAR T-cellsCS 1 Targeted CAR T-cellsSLAMF7-targeted CAR-T cellsSLAMF-7-targeted CAR-T cellsSLAMF 7-targeted CAR-T cellsCD319-targeted CAR-T cellsCD-319-targeted CAR-T cellsCD 319-targeted CAR-T cells
02
Targets
CD247 (T-cell surface glycoprotein CD3 epsilon chain)CD28 (Cluster of Differentiation 28)SLAMF7 (Signaling lymphocytic activation molecule family member 7)
Beyond the preview
Go deeper on CS1-targeted CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CS1-targeted CAR-T cells.